by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION We aimed to compare gait between individuals with Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), and cognitively unimpaired (CU) individuals and to evaluate the association between gait and regional amyloid beta (Aβ) burden in...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION No studies in India have explored subjective cognitive decline (SCD), a hallmark of stage II of preclinical Alzheimer’s disease. This study aims to assess the prevalence and correlates of SCD in a South Indian, urban, elderly population....
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION Tau pathology impacts neurodegeneration and cognitive decline in Alzheimer’s disease (AD), with the dorsal raphe nucleus (DRN) being among the brain regions showing the earliest tau pathology. As a serotonergic hub, DRN activity is altered...
by Clinical Neuropsychologist | Thursday, February 6, 2025 | Dementia
Abstract Understanding of the biology of Alzheimer’s disease (AD) has long been fragmented, with various investigators concentrating on amyloid beta (Aβ) or tau, inflammation, cell death pathways, misfolded proteins, glia, and more. Yet data from multiple...
by Clinical Neuropsychologist | Wednesday, February 5, 2025 | Dementia
Abstract INTRODUCTION The Alzheimer’s Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p-tau) assays provide the largest fold-changes in Alzheimer’s disease (AD) versus non-AD...
